Stoke Therapeutics (NASDAQ:STOK) Issues Quarterly Earnings Results

Stoke Therapeutics (NASDAQ:STOK) announced its quarterly earnings results on Monday. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.22), FiscalAI reports. The firm had revenue of $1.40 million during the quarter, compared to the consensus estimate of $5.32 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.

Stoke Therapeutics Trading Up 2.3%

Shares of STOK stock traded up $0.77 during midday trading on Monday, reaching $33.96. 554,699 shares of the stock were exchanged, compared to its average volume of 749,549. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $40.22. The firm has a market cap of $1.94 billion, a PE ratio of 50.69 and a beta of 1.07. The company’s 50 day moving average is $32.71 and its two-hundred day moving average is $29.70.

Insider Activity at Stoke Therapeutics

In related news, insider Arthur Tzianabos sold 4,355 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total transaction of $174,200.00. Following the sale, the insider directly owned 31,339 shares in the company, valued at $1,253,560. The trade was a 12.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Adrian R. Krainer sold 33,243 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total value of $1,321,076.82. Following the completion of the sale, the director directly owned 283,302 shares in the company, valued at approximately $11,258,421.48. The trade was a 10.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of STOK. Bank of Montreal Can purchased a new position in Stoke Therapeutics during the 4th quarter valued at about $287,000. Farallon Capital Management LLC purchased a new stake in Stoke Therapeutics in the fourth quarter worth about $286,000. Vestcor Inc bought a new position in shares of Stoke Therapeutics during the third quarter valued at approximately $239,000. LPL Financial LLC bought a new position in shares of Stoke Therapeutics during the fourth quarter valued at approximately $234,000. Finally, Jane Street Group LLC lifted its holdings in shares of Stoke Therapeutics by 125.2% during the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after purchasing an additional 15,001 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms recently issued reports on STOK. HC Wainwright raised their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. UBS Group set a $50.00 price objective on Stoke Therapeutics in a research report on Monday, December 15th. Loop Capital set a $35.00 target price on Stoke Therapeutics in a research note on Monday, January 5th. Wedbush upped their target price on Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a report on Monday, January 12th. Finally, Canaccord Genuity Group lifted their price target on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.25.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.